Summary

This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Awareness of biomarkers and predictors of disease activity in lupus
  • Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies
  • Impact of availability of a biomarker on willingness to prescribe a therapy
  • Implementing a potential IFN biomarker test in clinical practice
  • Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker
  • Barriers to using IFN signature test to stratify patients in clinical practice
  • Impact of data suggesting that high IFN? gene expression is closely associated with SLE on opinion of anifrolumab’s efficacy
  • Impact of data suggesting that high IFN? gene expression is more closely associated with LN than IFN? on opinion of anifrolumab’s efficacy




Key Highlights

  • Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test
  • Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies
  • Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab.




Scope

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
  • In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
  • Interviews performed in December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma’s analysts.




Reasons To Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "Biomarker Potential of Type I IFN Gene Signature in Lupus"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.